385 related articles for article (PubMed ID: 22691619)
1. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.
Wang SL; Ohrmund L; Hauenstein S; Salbato J; Reddy R; Monk P; Lockton S; Ling N; Singh S
J Immunol Methods; 2012 Aug; 382(1-2):177-88. PubMed ID: 22691619
[TBL] [Abstract][Full Text] [Related]
2. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab.
Hernández-Breijo B; Chaparro M; Cano-Martínez D; Guerra I; Iborra M; Cabriada JL; Bujanda L; Taxonera C; García-Sánchez V; Marín-Jiménez I; Barreiro-de Acosta M; Vera I; Martín-Arranz MD; Mesonero F; Sempere L; Gomollón F; Hinojosa J; Gisbert JP; Guijarro LG;
Biochem Pharmacol; 2016 Dec; 122():33-41. PubMed ID: 27664854
[TBL] [Abstract][Full Text] [Related]
3. Significance of low level infliximab in the absence of anti-infliximab antibodies.
Ungar B; Anafy A; Yanai H; Ron Y; Yavzori M; Picard O; Fudim E; Loebstein R; Kopylov U; Chowers Y; Dotan I; Eliakim R; Ben-Horin S
World J Gastroenterol; 2015 Feb; 21(6):1907-14. PubMed ID: 25684959
[TBL] [Abstract][Full Text] [Related]
4. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
Vande Casteele N; Gils A; Singh S; Ohrmund L; Hauenstein S; Rutgeerts P; Vermeire S
Am J Gastroenterol; 2013 Jun; 108(6):962-71. PubMed ID: 23419382
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.
Kopylov U; Mazor Y; Yavzori M; Fudim E; Katz L; Coscas D; Picard O; Chowers Y; Eliakim R; Ben-Horin S
Inflamm Bowel Dis; 2012 Sep; 18(9):1628-33. PubMed ID: 22038899
[TBL] [Abstract][Full Text] [Related]
6. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.
Vande Casteele N; Buurman DJ; Sturkenboom MG; Kleibeuker JH; Vermeire S; Rispens T; van der Kleij D; Gils A; Dijkstra G
Aliment Pharmacol Ther; 2012 Oct; 36(8):765-71. PubMed ID: 22928581
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA
Am J Gastroenterol; 2014 Jul; 109(7):1055-64. PubMed ID: 24796769
[TBL] [Abstract][Full Text] [Related]
8. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
Van Stappen T; Billiet T; Vande Casteele N; Compernolle G; Brouwers E; Vermeire S; Gils A
Inflamm Bowel Dis; 2015 Sep; 21(9):2172-7. PubMed ID: 26284296
[TBL] [Abstract][Full Text] [Related]
9. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
[TBL] [Abstract][Full Text] [Related]
11. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.
Imaeda H; Andoh A; Fujiyama Y
J Gastroenterol; 2012 Feb; 47(2):136-43. PubMed ID: 21953314
[TBL] [Abstract][Full Text] [Related]
12. Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay.
Hock BD; McKenzie JL; Goddard L; Smith SM; McEntyre CJ; Keating PE
Ther Drug Monit; 2018 Dec; 40(6):705-715. PubMed ID: 30439789
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay.
Wang SL; Hauenstein S; Ohrmund L; Shringarpure R; Salbato J; Reddy R; McCowen K; Shah S; Lockton S; Chuang E; Singh S
J Pharm Biomed Anal; 2013 May; 78-79():39-44. PubMed ID: 23454676
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
[TBL] [Abstract][Full Text] [Related]
15. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
Ben-Horin S; Yavzori M; Katz L; Kopylov U; Picard O; Fudim E; Coscas D; Bar-Meir S; Goldstein I; Chowers Y
Gut; 2011 Jan; 60(1):41-8. PubMed ID: 20519742
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
Stubenrauch K; Wessels U; Lenz H
J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787
[TBL] [Abstract][Full Text] [Related]
17. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.
Steenholdt C; Ainsworth MA; Tovey M; Klausen TW; Thomsen OO; Brynskov J; Bendtzen K
Ther Drug Monit; 2013 Aug; 35(4):530-8. PubMed ID: 23765033
[TBL] [Abstract][Full Text] [Related]
18. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
19. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
[TBL] [Abstract][Full Text] [Related]
20. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.
Plasencia C; Pascual-Salcedo D; Nuño L; Bonilla G; Villalba A; Peiteado D; Díez J; Nagore D; del Agua AR; Moral R; Martin-Mola E; Balsa A
Ann Rheum Dis; 2012 Dec; 71(12):1955-60. PubMed ID: 22563028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
